Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Food Based Intervention Rich in Plant Components to Improve Metabolic Health in Prediabetics (FBIP) Study

9 marca 2022 zaktualizowane przez: JeyaKumar Henry, Clinical Nutrition Research Centre, Singapore
The estimated prevalence of type 2 diabetes and prediabetes in Singapore will be approximately 20% and 25% respectively by the year 2035. Therefore, effective population based interventions are urgently warranted to halt this burden. Lifestyle intervention is the cornerstone of diabetes prevention and even remission. For example, dietary patterns such as the Mediterranean diet, Dietary Approaches to Stop Hypertension (DASH) diet etc. have all been shown to reduce risk of type 2 diabetes incidence. Therefore, given the successful utility of various dietary patterns, this randomized controlled trial will investigate the effectiveness of a food based dietary intervention, within an Asian dietary context, using legumes, low glycemic index (GI) starches (i.e., rice, noodles etc.), healthier vegetable oil blend as well as herbs and spices to improve various markers metabolic health, including glucose homeostasis in individuals with prediabetes.

Przegląd badań

Szczegółowy opis

The worldwide prevalence of type 2 diabetes has increased by more than two-fold over the past three decades, with ~60% of diabetics in the world currently living in Asian countries. Type 2 diabetes occurs at a younger age and at lower body mass index (BMI < 22 kg/m2) in Asians as compared other ethnic groups. Among the various evidence based approaches to diabetes prevention, diet plays one of the most important roles. In particular, food based interventions are beginning to emerge as superior strategies in the prevention of type 2 diabetes compared to nutrient based approaches. It is important of course to align food based interventions to the cultural and region specific aspects of food choice and eating behavior if such lifestyle pattern is to be implemented in a given population. To this effect, the investigators will investigate the effects of a multiple food components in combination on metabolic health outcomes, within an Asian dietary context. This proposed study will be undertaken in prediabetics who are at greater life-time risk of developing type 2 diabetes than their normoglycemic counterparts.

Based on the current evidence, the investigators will design a food based intervention consisting of a diet rich in legumes, low GI starches (such as rice, noodles),healthier vegetable oil blends (such as rice bran, peanut, sesame seed and sunflower oils) as well as certain herbs and spices. As part of this study, each volunteer will be provided with 2 of their 3 meals per day, consisting of the above mentioned foods, for a period of 16 weeks. The control group will also be provided 2 meals per day, matched for the total calorie contents. The total calorie content of each provided meal will be approximately 500 kcal for males and 400 kcal for females. The difference in the calorie contents between the genders will be made up by using prepacked snacks. There will also be further differences in the snack types between the two intervention (treatment vs control) groups. While the treatment group will consist of healthier snacks such as seeds and wholemeal crackers, the control group snack ingredients will be made from refined flour biscuits etc. The remaining foods (free choice) during the day will be monitored regularly by the study dietitian to ensure a small calorie deficit that should lead to an approximately 5% weight loss in both intervention and control groups. Therefore, while it is expected that even the control group will achieve some metabolic health benefits during this 16 week dietary intervention (indirectly due to weight loss), the investigators anticipate that the treatment group will attain greater benefits as compared to the control group, due to the differences in their food constituents. The effects of dietary interventions on metabolic health will be assessed at every 4-8 week intervals. The primary outcome measures will include several markers of glucose homeostasis (including HbA1c, fasting glucose, fasting insulin and a 2-hr oral glucose tolerance test [OGTT]). The secondary outcomes will include blood lipid profile, fructosamine, adiponectin, markers of oxidative stress and chronic inflammation.

Typ studiów

Interwencyjne

Zapisy (Oczekiwany)

125

Faza

  • Nie dotyczy

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

      • Singapore, Singapur, 117599
        • Clinical Nutrition Research Centre

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

45 lat do 75 lat (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria:

  • Chinese Male or Female• Age between 45-75 years
  • Body mass index 19.5-32.0 kg/m2
  • Deemed to be prediabetic based on meeting any 1 of 3 following criteria:1. Fasting blood glucose >5.5 mmol/l and <7.0 mmol/l2. Oral glucose tolerance test (OGTT) level >/=7.8 mmol/l and </=11.0 mmol/l3. Haemoglobin A1c (HbA1c) level >/=5.7 and </=6.4%.

Exclusion criteria:

  • Smoking
  • Having allergies or intolerances to any common food ingredients including eggs, fish, milk, peanuts, and tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings, etc.
  • Following special diets or having intentional dietary restrictions (e.g, vegetarians/vegans)
  • Not willing to adhere to diet modification as in the study protocol
  • Not willing to stop any strenuous activity during or within 24 hours of test days (for those actively participating in sports at the competitive and/or endurance levels)
  • Having glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
  • Having alcohol consumption on > 4 days per week with ≥ 6 alcoholic drinks per week
  • Having sustained elevation of blood pressure (>160/95 mm Hg)
  • Having previously undergone any gastrointestinal surgery or having history of gastrointestinal disorders
  • Having a history of heart, liver, kidney, blood disorders (e.g., thalassemia) or thyroid dysfunctions
  • Diabetic
  • Having history of tuberculosis, HIV, Hepatitis B or Hepatitis C infections
  • Having any prescription medication or any other alternative medicines or supplements which may interfere with study measurements in the in the opinion of the study investigators
  • Having antibiotics or suffering from diarrhea within the last 3 months
  • Having donated blood within 4 weeks of study participation
  • Having poor veins or having history of severe vasovagal syncope (blackouts or fainting) from blood draws
  • Having more than 5% weight loss or gain over the past 3 months
  • For female volunteers: menstruation within past 12 months or being on hormone replacement therapy

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Inny
  • Przydział: Randomizowane
  • Model interwencyjny: Przydział równoległy
  • Maskowanie: Pojedynczy

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Inny: Low-Calorie Control Group
The control group will receive for 2 calorie-restricted balanced meals per day, consisting of a portion of meat, a portion of vegetables, a portion of medium to high GI carbohydrates and prepared with refined corn oil. The control meals will be devoid of any whole legumes and will contain minimal amounts of spices. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
Twice a day reduced calorie frozen ready meals (balanced composition) to substitute participants' two main meals/day consecutively for a period of 16 weeks.
Aktywny komparator: Low-Calorie Treatment Group
The treatment group will receive for 2 calorie-restricted (isocaloric with control group) meals per day containing 100 g cooked whole legumes (amounting to a total of 200 g cooked legumes, approximately 1 cup of cooked legumes)and/or certain meat analogues (textured vegetable [soy] proteins), and/or a portion of vegetables, low GI, wholegrain carbohydrates for their starch sources (rice/noodles/pasta), added spices (dried spice powder) at dietary and culinary acceptable doses and blended vegetable oil. The third meal of the day and any additional snacks will be left to the free choice of the participants with calorie advice provided by study dietitian. Calorie restriction aims to reduce weight of participants by ~5%.
Twice a day reduced calorie frozen ready meals (rich in plant components) to substitute participants' two main meals/day consecutively for a period of 16 weeks.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
HbA1c
Ramy czasowe: 16 weeks
mmol/mol (%)
16 weeks
Fasting glucose
Ramy czasowe: 16 weeks
mmol/L
16 weeks
Fasting insulin
Ramy czasowe: 16 weeks
pmol/L
16 weeks
Oral Glucose Tolerance Test
Ramy czasowe: 16 weeks
mmol/L
16 weeks

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Białko C-reaktywne
Ramy czasowe: 16 tygodni (od pierwszej do ostatniej wizyty pomiarowej), mierzony co 8 tygodni
mg/L
16 tygodni (od pierwszej do ostatniej wizyty pomiarowej), mierzony co 8 tygodni
Blood Lipid Profile (HDL, LDL, Total Cholesterol, Triglyceride)
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 4 weeks
mmol/L
16 weeks (from first to final measurement visits), measured every 4 weeks
Fructosamine
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 4 weeks
µmol/L
16 weeks (from first to final measurement visits), measured every 4 weeks
Plasma Adiponectin
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 4 weeks
μg/mL
16 weeks (from first to final measurement visits), measured every 4 weeks
Oxidised LDL
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 4 weeks
ng/mL
16 weeks (from first to final measurement visits), measured every 4 weeks
IL-6 (interleukin 6)
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 8 weeks
pg/mL
16 weeks (from first to final measurement visits), measured every 8 weeks
TNF (Tumor Necrosis Factor - alpha)
Ramy czasowe: 16 weeks (from first to final measurement visits), measured every 8 weeks
pg/mL
16 weeks (from first to final measurement visits), measured every 8 weeks

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

2 listopada 2020

Zakończenie podstawowe (Oczekiwany)

9 sierpnia 2022

Ukończenie studiów (Oczekiwany)

9 sierpnia 2022

Daty rejestracji na studia

Pierwszy przesłany

1 lutego 2021

Pierwszy przesłany, który spełnia kryteria kontroli jakości

8 lutego 2021

Pierwszy wysłany (Rzeczywisty)

9 lutego 2021

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

11 marca 2022

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

9 marca 2022

Ostatnia weryfikacja

1 marca 2022

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • 2019/00997

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Badania kliniczne na Cukrzyca

Subskrybuj